文献速递冠心病血脂与心血管预防

风险加权载脂蛋白B:一种优于传统脂质生物标志物的冠心病风险预测新指标

Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.
PubMed 文献 · Eur Heart J · 2026-01-01

研究基于英国生物银行数据开发了风险加权载脂蛋白B(RW-apoB),该指标整合甘油三酯、脂蛋白(a)和载脂蛋白B,以反映LDL、富含甘油三酯脂蛋白/残粒及Lp(a)的致动脉粥样硬化风险。RW-apoB可显著重新分类个体风险,并在英国生物银行及另外三个人群队列中一致优于载脂蛋白B预测冠心病风险。

要点

  • RW-apoB整合甘油三酯、Lp(a)和apoB,单值反映三类脂蛋白颗粒风险。
  • 与apoB相比,52%个体风险排名变动≥10个百分位。
  • RW-apoB预测冠心病风险显著优于apoB(Harrell‘s C-index P<.0001)。

核心结论

  • RW-apoB不仅反映颗粒数量,还纳入TRL和Lp(a)的更高致动脉粥样硬化性,在冠心病风险分层方面提供有临床意义的改善。

研究设计与样本

  • 基于英国生物银行数据开发RW-apoB,并在英国生物银行及另外三个大型人群队列中验证其风险预测性能。

主要发现

  • 与按实测apoB排名相比,52%的个体风险排名上调或下调≥10个百分位。
  • 处于RW-apoB最高五分位且TRL和Lp(a)升高者的冠心病事件率为5.4%,其中约三分之一被apoB错误分类为较低风险。
  • 处于实测apoB最高五分位但TRL和Lp(a)较低者的事件率为3.9%,被正确地下调风险等级。
  • RW-apoB较apoB显著提高Harrell's C-index(P < .0001)。
  • 在接受他汀治疗者中,RW-apoB可能是更好的残余风险指标;在Cox模型中,RW-apoB在英国生物银行和另外三个大型人群队列中一致优于apoB。

关键数值与推荐

  • RW-apoB计算公式:RW-apoB = 11.65×TG(mmol/L) + 0.215×脂蛋白(a)(nmol/L) + 0.736×apoB(mg/dL)。

临床怎么用

  • 在临床风险评估中,可考虑使用RW-apoB替代或补充apoB,以更全面捕捉TRL和Lp(a)升高带来的冠心病风险。
  • 对于他汀治疗患者,RW-apoB可能有助于评估残余风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: LDL-C and non-HDL-C do not fully capture coronary heart disease (CHD) risk attributed to all apoB-containing lipoproteins. Use of apolipoprotein B (apoB) as a marker of total atherogenic particle number improves risk prediction, but risk may still be underestimated when triglyceride-rich lipoproteins (TRL/remnants) and lipoprotein(a) [Lp(a)] are elevated. The aim was to formulate a new metric-risk-weighted apoB (RW-apoB)-designed to capture risk from LDL, TRL/remnants, and Lp(a) in a single number. METHODS: Based on previously published estimates of the relative atherogenicity of LDL, TRL/remnant, and Lp(a) particles, RW-apoB was developed (using UK Biobank data) as an atherogenicity-weighted apoB-sum calculated as: RW-apoB = 11.65×TG(mmol/L) + 0.215×lipoprotein(a)(nmol/L) + 0.736×apoB(mg/dL). RESULTS: Assigning RW-apoB to individuals substantially reclassified their risk status. Compared with ranking by measured apoB, 52% of individuals were up- or down-ranked by ≥10 percentiles. About one-third of those in the top RW-apoB quintile-with elevated TRL and Lp(a) and a CHD event rate of 5.4%-were misclassified as lower risk by apoB. Conversely, individuals in the top measured apoB quintile but with low TRL and Lp(a) had a lower event rate (3.9%) and were correctly down-ranked. RW-apoB improved risk prediction, significantly increasing Harrell's C-index relative to apoB (P < .0001). In statin-treated subjects, RW-apoB was potentially a better index of residual risk. RW-apoB consistently outperformed apoB as a risk predictor in Cox models across the UK Biobank and three other large population cohorts. CONCLUSIONS: RW-apoB represents not only particle number but also accounts for the higher atherogenicity of TRL and Lp(a). It offers clinically meaningful improvements in CHD risk stratification.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Rehman MB, Björnson E, Adiels M, et al. Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease. Eur Heart J. 2026. PMID: 41568673. doi:10.1093/eurheartj/ehaf1124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。